


Dear Friends and Collaborators of Protagen

the summer has gone and a busy autumn lays ahead of us. Thus, it is time to update you on the latest developments at Protagen: We reached a significant milestone in July and launched our first ELISA research use test kit for Systemic Sclerosis (SSc), the ADx[®]SSc Multilisa[®], in an area that is currently the focus of many Pharma companies. Although this is a major breakthrough for us it is not the only news worth reporting, so we hope that you will enjoy reading our new look "Stratified News from Dortmund" and are looking forward to receiving any feedback you may have.



Protagen launches First SSC Research Test



Protagen has focused on the identification of a new class of biomarkers for SSC to augment current diagnostic tools. The combination of two standard markers with two proprietary, novel autoantigens delivered by our **SeroTag[®]** technology platform, are what gives the **ADx[®]SSc Multilisa[®]** real power to aid medical research in SSC. This novel research tool will support medical investigations in the field of SSC, e.g. for early disease recognition or stratification, and further clinical testing has started.

Conference Attendance



This year's **ECTRIMS Conference** took place in Boston. Protagen had numerous interesting meetings with Pharma and academics to discuss our latest development programs in NMO and MS. **The German Society for Rheumatology Meeting** in Duesseldorf allowed for several meetings with existing and potential collaboration and clinical partners. We also presented a poster on our RA development program together with our collaboration partners from HHU, Duesseldorf and Charité, Berlin.

Corporate News & PR



In recent months we wrote various company profiles to increase our visibility: We have or will appear in the **16th German Biotech Guide**, the **Gate to a Powerful Network** by VBU and **Going Public Magazin**. On August 20th, Mrs. Poschmann, Member of German Parliament (MdB) and a delegation from German Private Equity and Venture Capital Association e.V. (BVK) visited Protagen to discuss financing options and constraints for German Biotech companies.

QUARTERLY UPDATE

Since our last quarterly update we have advanced several of our in-house development programs in particular in RA and SLE and intend to initiate product development on both programs in early 2015. A collaboration project with a therapeutic vaccine was successfully concluded. The area holds significant promise for Protagen and will broaden the future scope of applications. In addition, an advanced co-development program with a leading diagnostic company shows novel product options in infectious diseases. The Pfizer project continuous to run smoothly and should be completed by the end of the year.

NEWS & FINALLY

Protagen AG Launches Landmark First Research Test Kit for Systemic Sclerosis

Protagen AG, a company dedicated to the development of powerful diagnostic tools to address some of the most severe autoimmune diseases, has launched its first ELISA research use test kit for Systemic Sclerosis (SSc), the ADx[®]SSc Multilisa[®]...

Meet us @

Protagen will be at various meetings & conferences in the upcoming months and is looking forward to meeting you at:

- **Bioinvestor Forum**, San Francisco on Oct 7th & 8th
- **BioEurope**, Frankfurt on Nov 3rd to 5th
- **American College of Rheumatology**, Boston on Nov 15th to 19th
- **Biotech Showcase and JP Morgan**, San Francisco on Jan 12th to 16th

Finally

The Bundesliga season has started poorly for Borussia Dortmund. Despite the numerous visits and support from our employees they have yet to hit peak form but we are certain that the good news will be coming shortly from Borussia and Protagen.